Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Measure Better Investing in Racial Equity Beyond Aid Beyond Trade-offs Impact en las Americas New Revivalists Women Rising in India Operation Impact
Smarter Money Women Rising 2030 Finance Locavesting Inclusive Economy Regeneration Impact Tech New Power Geographies
Slack Conference Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Industry News Impact Management Good Business Personal Finance Faith and investing Billionaires
Gender Lens Investing Women Rising in India
SDGs Climate Finance Clean Energy Innovative Finance Full Stack Capital Long-termism
Opportunity Zones Investing in place
Entrepreneurship Return on Inclusion Good Jobs Inclusive Fintech Creative economy Housing New Schooled Well Being People on the Move
Conservation Finance Farmer Finance Financing Fish
Blockchain/AI/IoT Urban Tech Food Tech Inclusive Fintech
Human Rights Democracy and Peace News and Information
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States Growth Markets
Subscribe
Features
Series
Themes
Community
Data
Subscribe Log In
More

Women-led Pivotal bioVenture closes $300 million fund for early-stage drugs



Women Rising

Tracy Saxton, who was the investment director for the Roche Venture Fund and for SV Life Sciences Advisers, has closed the first fund for her new firm, Pivotal bioVenture Partners.

Pivotal is seeking to fill a capital gap in early-stage treatments between drug discovery and early clinical development.

Saxton was backed by the Nan Fung Group in Hong Kong. Healthcare, like finance and tech, is notoriously light on women leaders.

Increasingly, women are starting their own healthcare investment funds rather than trying to climb the ranks of established firms, says GE Ventures’ Lisa Suennen.

Biomatics Capital, co-led by Julie Sunderland, formerly with the Bill & Melinda Gates Foundation, recently announced it had raised $200 million for its first fund.

This post originally appeared in ImpactAlpha’s daily newsletter. Get The Brief.

Photo credit: Endpoints News

You might also like...